Literature DB >> 6456886

The role of the laboratory in the planned use of cefoperazone for the treatment of difficult Pseudomonas infections.

M McDonald, H Miles, M Carson.   

Abstract

Four cases are discussed illustrating the role of the laboratory in the treatment of difficult pseudomonas infections. Pseudomonas vertebral osteomyelitis, in a 76-year-old man with impaired renal function, was successfully treated with cefoperazone given for 7 weeks. A 73-year-old woman, who had recurrent pseudomonas septicaemia due to infected cardiac pacing wires (that could not be removed), was managed with long term daily intramuscular cefoperazone, and a 31-year-old woman with pseudomonas aortitis was treated with long term intravenous cefoperazone. A 47-year-old man, who developed a pseudomonas infection superimposed on chronic osteomyelitis of the femur prior to a free vascularised graft operation, was treated with cefoperazone and ticarcillin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456886     DOI: 10.2165/00003495-198100221-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Pseudomonas lumbar diskitis.

Authors:  A R Amine; J L Salazar
Journal:  IMJ Ill Med J       Date:  1977-02

2.  Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

Authors:  L Balant; P Dayer; M Rudhardt; A F Allaz; J Fabre
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

3.  A study of cefoperazone alone and in combination with tobramycin against Pseudomonas aeruginosa.

Authors:  E R Pavillard; H Miles
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  Spinal Pseudomonas chondro-osteomyelitis in heroin users.

Authors:  R Lewis; S Gorbach; P Altner
Journal:  N Engl J Med       Date:  1972-06-15       Impact factor: 91.245

5.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.